NDC	Product Description	Pack Size	WAC	Launch Date	Marketing and Pricing Plans	Estimated Patient Volume	Breakthrough Therapy Designation	Priority Review	
70710-1159-03	Mirabegron ER Tab 25mg	30	\$397.70	4/19/2024		As Zydus distributes generic products, we do not estimate the number of patients that may be prescribed our products. Volume is based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Volumes are also based on national level data, and we do not break these estimates down to a patient or state level.	No	No	N/A
70710-1159-09	Mirabegron ER Tab 25mg	90	\$1,193.10		Zydus does not market or promote its generic products to prescribers or patients. Zydus sells its products to retailers and wholesalers. Zydus prices its products based on the current market conditions.	As Zydus distributes generic products, we do not estimate the number of patients that may be prescribed our products. Volume is based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Volumes are also based on national level data, and we do not break these estimates down to a patient or state level.	No	No	N/A
70710-1160-03	Mirabegron ER Tab 50mg	30	\$397.70	4/22/2024	Zydus does not market or promote its generic products to prescribers or patients. Zydus sells its products to retailers and wholesalers. Zydus prices its products based on the current market conditions.	As Zydus distributes generic products, we do not estimate the number of patients that may be prescribed our products. Volume is based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Volumes are also based on national level data, and we do not break these estimates down to a patient or state level.	No	No	N/A
70710-1160-09	Mirabegron ER Tab 50mg	90	\$1,193.10	4/22/2024	Zydus does not market or promote its generic products to prescribers or patients. Zydus sells its products to retailers and wholesalers. Zydus prices its products based on the current market conditions.	As Zydus distributes generic products, we do not estimate the number of patients that may be prescribed our products. Volume is based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Volumes are also based on national level data, and we do not break these estimates down to a patient or state level.	No	No	N/A